消岩汤治疗甲状腺癌术后患者维持治疗期的临床观察研究

Clinical observation of Xiaoyan Decoction in the treatment of postoperative patients with thyroid cancer

[目的]观察消岩汤对甲状腺癌术后患者维持治疗期的临床疗效。[方法]62例甲状腺癌术后患者随机分为治疗组与对照组。治疗组32例,予消岩汤联合左甲状腺素钠片治疗,对照组30例,单纯服用左甲状腺素钠片。观察两组治疗前后生活质量评分、血清促甲状腺激素(TSH)、血清甲状腺球蛋白(TG)、血清游离三碘甲腺原氨酸(FT3)及血清游离甲状腺素(FT4)、免疫功能指标(T淋巴细胞亚群水平)的变化。[结果]与对照组比较,治疗组临床症状改善率明显提高(P<0.01)。与本组治疗前比较,治疗组患者血TSH和TG值下降显著(P<0.01),总T细胞(CD3+)、T辅助/诱导淋巴细胞(CD3+/CD4+)、T抑制/毒性淋巴细胞(CD3+/CD8+)、B淋巴细胞(CD3-/CD19+)、NK淋巴细胞(CD3-/CD16+56+)明显高于对照组(P<0.01)。[结论]在甲状腺癌患者维持治疗期,消岩汤能够减轻甲状腺癌术后内分泌治疗不良反应,具有提高甲状腺癌术后患者的机体免疫功能趋势,一定程度预防甲状腺癌复发风险,改善患者的生活质量。

[Objective]To observe the clinical efficacy of Xiaoyan Decoction on the postoperative maintenance period of thyroid cancer.[Methods]Thirty patients with thyroid cancer were randomly Divided into the treatment group and the control group.Fifteen patients in the treatment group were treated with Xiaoyan Decoction combined with levothyroxine sodium tablets;Fifteen patients in the control group were treated with levothyroxine sodium tablets alone.The quality of life scores,serum thyroid stimulating hormone(TSH),serum thyroglobulin(TG),serum free triiodothyronine(FT3),serum free thyroxine(FT4)and immune function indicators(T lymphocyte subsets)were measured before and after treatment.[Results]Compared with the control group,the clinical symptom improvement rate of the treatment group was significantly improved(P<0.01).Compared with before treatment,the patients in the treatment group had significant decrease in blood TSH and TG values(P<0.01),immune function indicators[total T cells(CD3+),T-assisted/induced lymphocytes(CD3+/CD4+),T-inhibitory/toxic lymphoids cells(CD3+/CD8+),B lymphocytes(CD3-/CD19+),and NK lymphocytes(CD3-/CD16+56+)]were significantly higher than the control group(P<0.01).[Conclusion]In the maintenance treatment period of patients with thyroid cancer,Xiaoyan Decoction can reduce the side effects of endocrine therapy after thyroid cancer surgery,improve the body’s immune function after thyroid cancer surgery,prevent the risk of thyroid cancer recurrence and improve the quality of life of patients.